Pearl

AI-powered dental X-ray diagnostics platform

PUBLIC


Name	Pearl
Tagline	AI-powered dental X-ray diagnostics platform
Headquarters	West Hollywood, California, United States
Founded	2019
Stage	Series B
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	$50M+ (total disclosed ~$69,000,000)

Executive Summary

PUBLIC Pearl is an AI diagnostics platform for dentistry that has secured a first-mover advantage through regulatory clearance, a position it is now capitalizing on with a $58 million Series B round [TechCrunch, July 2024]. Founded in 2019 by Ophir Tanz, the company's core product, Second Opinion®, was the first AI software cleared by the FDA to read dental X-rays, a milestone that provides a tangible wedge into a traditionally conservative market [TechCrunch, July 2024]. Tanz's background as the founder of GumGum, a computer vision company that scaled to over $100 million in revenue, provides a relevant operational track record for building and commercializing AI-powered visual analysis tools [Forbes, 2017]. The company operates a B2B software model, selling to dental practices and reporting aggressive top-line growth of 458% in 2023, though from a base of $11.1 million [TechCrunch, July 2024] [Latka]. The recent funding, led by Left Lane Capital at a $400 million post-money valuation, is the largest disclosed round in the dental AI category to date [Los Angeles Business Journal, July 2024]. Over the next 12-18 months, the key watchpoints are the validation of its high growth claims through named customer deployments, the execution of its partnership with Curve Dental's platform, and its ability to defend its regulatory lead against better-funded competitors like Overjet. Data Accuracy: YELLOW -- Key claims (FDA clearance, funding round, valuation) are confirmed by multiple outlets; revenue and growth metrics rely on single, unverified sources.

Taxonomy Snapshot

Axis	Classification
Stage	Series B
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	$50M+ (total disclosed ~$69,000,000)

Company Overview

PUBLIC Pearl was founded in 2019 by Ophir Tanz, a solo founder who previously built and scaled GumGum, a computer vision company focused on advertising technology [Crunchbase]. The company operates from West Hollywood, California, targeting the dental diagnostics market with an AI-powered platform. Its primary milestone came in 2022 when it secured FDA clearance for its Second Opinion® software, a first for an AI dental diagnostic aid [TechCrunch, July 2024].

Key developments followed a clear funding cadence. Pearl raised an $11 million Series A in 2021, which supported the initial product development and regulatory efforts [Crunchbase]. The company then announced a $58 million Series B in July 2024, led by Left Lane Capital, which was reported as the largest single investment in the dental AI sector to date [Los Angeles Business Journal, July 2024]. This round valued the company at $400 million post-money [Los Angeles Business Journal, July 2024].

Operational milestones include building a team of 79 people by 2023 (estimated) and integrating its software with third-party platforms like Curve Dental's SuperHero™, which serves over 80,000 users [LinkedIn]. The company claims its technology is now used by dental practices across six continents [Dental Products Report].

Data Accuracy: YELLOW -- Key facts like founding date and funding rounds are confirmed by multiple sources. The 2023 team size and specific integration claims are based on single-source reports.

Product and Technology

MIXED Pearl's product strategy is built on a two-pillar platform, anchored by the first FDA-cleared AI diagnostic in its category. The company's primary offering, Second Opinion®, is a real-time radiologic aid that analyzes dental X-rays to detect pathologies like cavities and bone loss. According to the company, the software achieves a 94% diagnostic accuracy rate and is integrated directly into a practice's existing imaging workflow, providing visual overlays and annotations on radiographs [Pearl Website]. The core commercial claim is that this AI-assisted analysis drives a measurable business outcome: dentists using Second Opinion see, on average, a 30% increase in patient acceptance of recommended treatments [TechCrunch, July 2024]. This positions the tool not just as a clinical aid but as a revenue-enhancing layer for dental practices.

The second pillar, Practice Intelligence®, is a suite of operational software tools designed to analyze practice data. While specific features are not detailed in public materials, the product is described as focusing on efficiency and production growth [Perplexity Sonar Pro Brief]. The integration of both products into a single platform suggests a strategy to move beyond a point-solution diagnostic tool toward becoming a comprehensive practice management system. A significant deployment milestone is the integration of Pearl's software into the SuperHero™ platform by Curve Dental, which serves over 80,000 dental professionals [LinkedIn]. This partnership provides a substantial, pre-existing channel for distribution.

From a technology standpoint, the product is built on computer vision models trained to recognize dental pathologies. The engineering team's focus, [PUBLIC] inferred from active job postings, includes building and scaling machine learning platforms and full-stack systems to support these real-time diagnostic applications [Pearl Careers, 2026]. The company's first-mover regulatory status is a key differentiator; Second Opinion® holds FDA 510(k) clearance as a radiologic aid and is noted by the company as the only such software cleared for use in over 120 countries [Pearl Press Release]. This global regulatory footprint is a tangible barrier to entry for competitors.

Data Accuracy: YELLOW -- Product claims are sourced from the company website and press releases, with commercial outcomes (30% case acceptance boost) corroborated by a single third-party report. The integration with Curve Dental is noted on LinkedIn but lacks independent verification. Technical stack details are inferred from job postings.

Market Research

PUBLIC The market for AI in dental diagnostics is defined less by its current size and more by the structural shift it represents, moving from a manual, subjective clinical process toward a quantified, software-augmented standard of care. While Pearl and its competitors do not yet operate in a market with a widely cited, third-party TAM, the opportunity is framed by the scale of the underlying dental services industry and the specific pain points AI aims to address.

Demand is driven by a confluence of clinical and economic factors. Dentists face persistent diagnostic variability and the challenge of patient case acceptance; Pearl's own claim that its software increases case acceptance by 30% speaks directly to a core revenue pain point for practices [Pearl Website]. The broader adoption of digital radiography over the past decade has created a standardized, digital asset base that is now amenable to computer vision analysis. Furthermore, an aging population and growing emphasis on preventative care are increasing the volume of diagnostic imaging, creating operational pressure that efficiency tools like Practice Intelligence® are designed to relieve [Perplexity Sonar Pro Brief].

Adjacent and substitute markets provide useful analogies. The global dental consumables and equipment market was valued at over $30 billion in 2023, with diagnostic imaging systems representing a significant segment (analogous market, Grand View Research) [Grand View Research, 2023]. More directly, the market for AI in medical imaging across all specialties is projected to reach multi-billion dollar scale by the end of the decade, suggesting a substantial addressable niche within dentistry. The primary substitute remains the status quo: dentist expertise alone, supported by practice management software that handles scheduling and billing but not diagnostic analysis.

Regulatory clearance is not just a barrier to entry but a primary market-shaping force. The FDA's 510(k) clearance pathway, which Pearl navigated to secure the first clearance for a dental diagnostic AI in 2022, creates a significant moat for early movers [TechCrunch, July 2024]. This regulatory gate, combined with the clinical validation required, limits the field of competition to well-funded, technically sophisticated players rather than open-source or lightweight software tools. Macro forces include the ongoing consolidation of dental practices into larger DSOs (Dental Service Organizations), which may accelerate the adoption of standardized, enterprise-grade software solutions to drive efficiency across networks.

Global Dental Consumables Market (2023) | 30 | $B
AI in Medical Imaging Market (2030 est.) | 4.5 | $B

The available sizing data points to a substantial underlying industry, with the AI segment's growth trajectory still being defined. The $4.5 billion projection for broader medical imaging AI by 2030, while not specific to dentistry, suggests the potential scale if adoption follows a similar path in oral healthcare.

Data Accuracy: YELLOW -- Market sizing figures are from analogous, broader industry reports. Specific TAM/SAM for dental AI diagnostics is not confirmed by a dedicated third-party study.

Competitive Landscape

MIXED Pearl operates in a narrow but high-stakes segment where regulatory clearance is a primary moat, creating a near-term oligopoly of three venture-backed AI diagnostic providers.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Pearl	AI-powered dental X-ray diagnostics platform	Series B / ~$69M total	First FDA-cleared AI dental diagnostic (Second Opinion®) in 2022	[TechCrunch, July 2024]
Overjet	AI analytics for dental insurers and providers	Series C / $53M raised March 2024	Focus on payer-side analytics and claims adjudication; valuation reported at $550M	[Perplexity Sonar Pro Brief]

The competitive map splits along two axes. The first is clinical versus administrative workflow. Pearl and Video Health are anchored in the clinical side, providing direct diagnostic support to dentists during patient consultations. Overjet, while also using AI on radiographs, has built its initial wedge with dental insurers, analyzing claims and prior authorizations. The second axis is go-to-market. Pearl and Overjet pursue enterprise sales, with Pearl targeting individual dental practices and DSOs (Dental Service Organizations), while Overjet's reported customer base includes large insurers like Guardian Life [Perplexity Sonar Pro Brief]. Video Health's positioning suggests a focus on the growing direct-to-consumer and teledentistry channel.

Pearl's most defensible edge today is regulatory. Its Second Opinion® software holds the distinction of being the first AI radiologic aid cleared by the FDA for dental use, a claim corroborated by its 2022 press release [Pearl, 2022]. This clearance, which the company states is valid in over 120 countries, creates a significant barrier to entry for new pure-play AI diagnostics [Pearl Press Release]. The edge is durable insofar as the FDA process remains rigorous and time-consuming, but it is perishable. Competitors are actively seeking their own clearances, and Overjet's substantial funding provides ample resources to navigate the regulatory pathway. Pearl's first-mover status grants it early reference customers and clinical validation data, which can compound into a data network effect if its algorithms improve faster with more diverse practice data.

The company's most exposed flank is capital intensity and market focus. Overjet's last reported valuation of $550 million and its $53 million Series C in March 2024 suggest it has both a higher war chest and investor confidence to expand aggressively, potentially moving downstream into Pearl's core clinical practice market [Perplexity Sonar Pro Brief]. Furthermore, Pearl's model of selling to individual practices is notoriously fragmented and sales-intensive. If a larger incumbent in dental practice management software (e.g., Henry Schein, Patterson Dental) were to develop or acquire similar AI capabilities, they could use existing distribution to outflank Pearl's direct sales efforts. Pearl's partnership with Curve Dental, integrating into its SuperHero™ platform for 80,000+ users, is a defensive move against this very risk [LinkedIn].

The most plausible 18-month scenario is market segmentation hardening, not a winner-take-all outcome. The winner, if dental insurers accelerate adoption of AI for claims review, is Overjet, given its incumbent relationships and focus. The loser, if the direct-to-practice sales cycle proves longer and more costly than modeled, is the provider with the least capital efficiency,a risk for any capital-intensive sales model in a fragmented market. Pearl's recent $58 million Series B provides a substantial runway to prove its sales motion and expand its Practice Intelligence® suite, but the next year will test whether its clinical-first, practice-centric approach can achieve the growth required to justify its $400 million valuation against a better-funded competitor targeting the payer side.

Data Accuracy: YELLOW -- Competitor details are sourced from a single aggregated research brief; Pearl's own positioning and FDA status are publicly confirmed.

Opportunity

PUBLIC Pearl’s opportunity rests on transforming a fragmented, analog diagnostic process into a standardized, AI-driven workflow, creating a new category of clinical support software for a global dental industry that has been slow to adopt enterprise technology.

The headline opportunity is for Pearl to become the de facto clinical operating system for dental practices worldwide. This outcome is plausible because the company has already secured the foundational regulatory and technical clearances that competitors lack. Its Second Opinion® platform is the first-and-only AI radiologic aid cleared for use in over 120 countries, a significant head start in a field where regulatory approval is a primary barrier to entry [Pearl Press Release]. This clearance, combined with the reported 30% boost in patient treatment acceptance when dentists use the software, directly addresses two core practice needs: clinical defensibility and revenue growth [TechCrunch, July 2024]. The path from a point-solution diagnostic aid to an operating system is evidenced by the expansion of its product suite to include Practice Intelligence® for operational analytics, moving beyond diagnostics into practice management [Perplexity Sonar Pro Brief].

Pearl’s path to scale can be modeled through several concrete scenarios, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Embedded Standard	Pearl’s AI becomes a default, integrated feature within major practice management software (PMS) platforms, reaching hundreds of thousands of dentists indirectly.	The existing integration with Curve Dental’s SuperHero™ platform for 80,000+ users serves as a blueprint for similar deals with other large PMS vendors [LinkedIn].	The integration model is proven in healthtech; embedding reduces sales friction and creates a durable, low-touch revenue stream.
Enterprise & DSO Capture	Large Dental Service Organizations (DSOs), which operate hundreds of clinics under unified management, adopt Pearl as a corporate-wide standard for quality control and efficiency.	A single flagship partnership with a major DSO like Aspen Dental or Heartland Dental.	DSOs are consolidating the market and actively seek technology to standardize care and improve margins; Pearl’s FDA clearance is a key procurement requirement.
Diagnostic Expansion	The platform expands beyond caries detection to a full suite of oral pathology diagnostics (e.g., periodontal disease, oral cancer screening), increasing its average contract value and clinical indispensability.	Successful clinical validation and regulatory clearance for new diagnostic modules.	The core computer vision technology is modular; the company’s research hiring for machine learning scientists indicates ongoing R&D in this direction [Pearl Careers, 2026].

Compounding for Pearl would manifest as a data and distribution flywheel. Each new dental practice using Second Opinion® generates annotated radiographic data, which can be used to retrain and improve the AI models, widening the performance gap versus competitors. Improved accuracy and new features, in turn, strengthen the value proposition for the next wave of customers and partners. Early evidence of this flywheel is the claim of 94% diagnostic accuracy, a figure that likely benefits from a growing dataset [Pearl Website]. Furthermore, integrations like the one with Curve Dental create distribution lock-in; once a PMS vendor embeds Pearl’s API, switching costs for dental practices become high, and the vendor itself becomes a channel partner advocating for Pearl’s adoption.

The size of the win, should the Embedded Standard or DSO Capture scenarios materialize, can be framed by a comparable. Overjet, a direct competitor, raised a Series C at a $550 million valuation in March 2024 [Perplexity Sonar Pro Brief]. Pearl’s recent $400 million valuation post-Series B reflects a similar early-stage premium for a regulatory-cleared asset [Los Angeles Business Journal, July 2024]. If Pearl successfully transitions from a high-growth startup to a category-defining platform with embedded distribution, a plausible outcome is an acquisition or public market valuation in the low single-digit billions. This scenario is not a forecast but illustrates the premium attached to software that becomes a clinical standard in a large, underserved vertical.

Data Accuracy: YELLOW -- Key opportunity claims (regulatory clearance, integration) are from company sources; competitive benchmark and valuation are from single press reports.

Sources